Farewell to 2020! custercountychief.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from custercountychief.com Daily Mail and Mail on Sunday newspapers.
Moderna vaccine shows 94.1% efficacy in a Phase 3 clinical trial There were no safety issues found and the side effects have been mild, though more research is needed on its effect on transmission.
, Associate Editor
The investigational vaccine known as mRNA-1273 was 94.1% effective in preventing symptomatic COVID-19, according to preliminary results from a Phase 3 clinical trial reported in
The New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19, and investigators identified no safety concerns or evidence of vaccine-associated enhanced respiratory disease (VAERD).
The vaccine was codeveloped by Massachusetts-based Moderna and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Moderna and NIAID previously shared initial results from the COVE trial. On Dec. 18, 2020, the FDA issued an emergency use authorization allowing Moderna to make the vaccine available
E-Mail
IMAGE: Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, receives the Moderna COVID-19 vaccine at the HHS/NIH COVID-19 Vaccine Kick-Off event at NIH on 12/22/20.. view more
Credit: NIH
WHAT:
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the
New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD).
The vaccine was co-developed by Moderna, Inc., a biotechnology company based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Moderna and NIAID previously shared initial results from the COVE trial. On Dec. 18,
4. Setting aside space for people to quarantine
5. Protecting At-Risk Populations
6. Issuing Directed Health Measures
In addition to these steps, Nebraskans have been using the tools to slow the spread of the virus such as social distancing, wearing a mask to the store, washing hands often, and staying home when sick. Our communities have responded as expected by looking out for one another and doing the right thing.
As we’ve protected hospital capacity, we’ve also been working to help Nebraskans recover. The state steered federal coronavirus relief towards $411 million in grants for Nebraska’s businesses and family farms. This includes grants of $12,000 to 12,214 small businesses and 9,209 livestock producers with 75 or fewer employees. The funds also include stabilization grants to hotels and convention centers, zoos, ethanol producers, event centers and sports arenas. According to the Kansas City Federal Reserve Bank, “revenues generated
UNMC participating in test of new COVID vaccine candidate kearneyhub.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kearneyhub.com Daily Mail and Mail on Sunday newspapers.